Kerecis Announces New Directors Eythor Bender and Egill Masson
Reykjavik/Isafjordur, Iceland, October 8th, 2010 — Kerecis, the emerging tissue-regeneration company, today announced that Eythor Bender and Egill Masson were elected to the company’s Board of Directors at the Annual Meeting.
Bender is the CEO of Berkeley Bionics headquartered in San Francisco Bay Area. He was the former President of Ossur Americas and CEO of Rex Bionics. Previous to that he held various positions in marketing and sales for Hewlett Packard Europe. Bender spent 13 years in executive management with Ossur, a global leader in the development, manufacture and distribution of non-invasive orthopedic products. He served the last six years as president of Ossur Americas located in Southern California. Originally from Iceland, Bender lives in San Francisco.
Masson, the former CEO of Taugagreining, was instrumental in the sale of the company to CareFusion (previously Viasys) in 2004. Masson worked at Taugagreining for 16 years. Before becoming CEO, he was VP of Research & Development. He also served in various management positions in CareFusion from 2004 to 2008. Masson is currently an investment manager at the New Business Venture Fund based in Reykjavik, Iceland.
Kerecis is involved in the research, development and production of tissue-regeneration products that can be used in reconstructive, soft- and hard-tissue surgical procedures. For regulatory purposes, the company’s technology is classified as a medical device. The patent-pending Kerecis technology is currently in the development stage. Kerecis received its start-up financing in December 2009. The Kerecis team consists of experienced executives with proven track records in the development of medical-device businesses, in clinical development and in the protection of intellectual property.
Gudmundur F. Sigurjonsson, Kerecis Co-Founder and Chairman of the Board:
“The new directors bring significant business development and financial experience to the Board of Kerecis. This will be of considerable value as the company continues to implement its business plan and prepare for our Series A capital raise.”
Kerecis ehf is a recently incorporated company founded to develop novel tissue-regeneration technologies based on proprietary, fish-derived, protein technologies. For further information, visit the website (https://kerecis.com), e-mail email@example.com, or call 011-35- 562-2601.
For further information, contact:
Gudmundur F. Sigurjónsson, Chariman of Board, Kerecis ehf.
Phone (Iceland) +354 8494960 / (U.S.) (703) 879-6535